•
Dec 31, 2022

Hologic Q1 2023 Earnings Report

Revenue and EPS exceeded guidance, with double-digit organic revenue growth in Diagnostics and Surgical segments and increased full-year guidance.

Key Takeaways

Hologic reported a decrease in revenue by 27.0% to $1,074.2 million, but exceeded revenue expectations. Diagnostics and Surgical businesses experienced double-digit organic revenue growth ex. COVID-19. The company increased its full-year fiscal 2023 guidance for both revenue and EPS.

Each base franchise exceeded revenue expectations and delivered robust profitability.

Diagnostics and Surgical businesses achieved double-digit organic revenue growth ex. COVID-19.

Breast Health business showed encouraging signs of recovery.

Full-year fiscal 2023 guidance for revenue and EPS was increased.

Total Revenue
$1.07B
Previous year: $1.47B
-27.0%
EPS
$1.07
Previous year: $2.17
-50.7%
Gross Profit
$618M
Previous year: $986M
-37.4%
Cash and Equivalents
$2.44B
Previous year: $1.42B
+71.8%
Total Assets
$9.29B
Previous year: $9.29B
+0.1%

Hologic

Hologic

Hologic Revenue by Segment

Hologic Revenue by Geographic Location

Forward Guidance

Hologic expects low double-digit constant currency organic revenue growth ex. COVID-19 in each division for the second quarter and full year 2023.

Positive Outlook

  • Expects low double-digit constant currency organic revenue growth ex. COVID-19 in each division for the full-year fiscal 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income